OBSIDIAN THERAPEUTICS, INC. (OBX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $41.72M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.00K; Retained Earnings (Accumulated Deficit)USD $341.43M.
- 2026-04-10: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $29.87M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $23.00K; Retained Earnings (Accumulated Deficit)USD $295.94M.
OBSIDIAN THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.00K | $41.72M | $-3.00K | $341.43M | $-299.71M | 3 month · $1.55M |
| 2026-04-10 | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | $-276.20M | 3 month · $1.45M |
| 2025-12-31 | $1.00K | $29.87M | $23.00K | $295.94M | $-266.04M | 12 month · $8.93M |
| 2025-06-30 | (m) | (m) | (m) | (m) | $-221.44M | 3 month · $2.76M |
| 2025-03-31 | (m) | (m) | (m) | (m) | $-197.30M | 3 month · $2.11M |
| 2024-12-31 | $1.00K | $20.92M | $-27.00K | $195.33M | $-174.43M | 12 month · $7.06M |
| 2023-12-31 | (m) | (m) | (m) | (m) | $-100.88M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |